TRP Channels as Therapeutic Targets -

TRP Channels as Therapeutic Targets (eBook)

From Basic Science to Clinical Use

Arpad Szallasi (Herausgeber)

eBook Download: PDF | EPUB
2015 | 1. Auflage
536 Seiten
Elsevier Science (Verlag)
978-0-12-420079-1 (ISBN)
Systemvoraussetzungen
Systemvoraussetzungen
143,00 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen

TRP Channels as Therapeutic Targets: From Basic Science to Clinical Use is authored by experts across academia and industry, providing readers with a complete picture of the therapeutic potential and challenges associated with using TRP channels as drug targets.

This book offers a unique clinical approach by covering compounds that target TRP channels in pre-clinical and clinical phases, also offering a discussion of TRP channels as biomarkers.

An entire section is devoted to the novel and innovative uses of these channels across a variety of diseases, offering strategies that can be used to overcome the adverse effects of first generation TRPV1 antagonists.

Intended for all researchers and clinicians working toward the development of successful drugs targeting TRP channels, this book is an essential resource chocked full of the latest clinical data and findings.


  • Contains comprehensive coverage of TRP channels as therapeutic targets, from emerging clinical indications to completed clinical trials
  • Discusses TRP channels as validated targets, ranging from obesity and diabetes through cancer and respiratory disorders, kidney diseases, hypertension, neurodegenerative disorders, and more
  • Provides critical analysis of the complications and side effects that have surfaced during clinical trials, offering evidence-based suggestions for overcoming them

TRP Channels as Therapeutic Targets: From Basic Science to Clinical Use is authored by experts across academia and industry, providing readers with a complete picture of the therapeutic potential and challenges associated with using TRP channels as drug targets. This book offers a unique clinical approach by covering compounds that target TRP channels in pre-clinical and clinical phases, also offering a discussion of TRP channels as biomarkers. An entire section is devoted to the novel and innovative uses of these channels across a variety of diseases, offering strategies that can be used to overcome the adverse effects of first generation TRPV1 antagonists. Intended for all researchers and clinicians working toward the development of successful drugs targeting TRP channels, this book is an essential resource chocked full of the latest clinical data and findings. Contains comprehensive coverage of TRP channels as therapeutic targets, from emerging clinical indications to completed clinical trials Discusses TRP channels as validated targets, ranging from obesity and diabetes through cancer and respiratory disorders, kidney diseases, hypertension, neurodegenerative disorders, and more Provides critical analysis of the complications and side effects that have surfaced during clinical trials, offering evidence-based suggestions for overcoming them

Contributors


M. Allen McAlexander     Neuronal Targets Team, Respiratory Therapy Area, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA

Ganesan Baranidharan     Consultant in Pain Medicine, Leeds Teaching Hospitals NHS trust: D ward, Seacroft Hospital, Leeds, LS14 6UH

Ralf Baron     Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Germany

Arun K. Bhaskar     Consultant in Pain Medicine, Leeds Teaching Hospitals NHS trust: D ward, Seacroft Hospital, Leeds, LS14 6UH

Mahendra Bishnoi     Department of Nutritional Sciences, and Technology, National Agri-Food Biotechnology Institute (NABI), SAS Nagar, India

Jill-Desiree Brederson     Global Medical Communications, Research and Development, AbbVie Inc., North Chicago, Illinois, USA

Dorothy Cimino Brown     Veterinary Clinical Investigations Center and Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Nigel W. Bunnett     Monash Institute of Pharmaceutical Sciences, and Department of Pharmacology, The University of Melbourne, Parkville, Victoria, Australia

Ingolf Cascorbi     Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Kiel, Germany

Michael J. Caterina

Department of Neurosurgery

Department of Biological Chemistry

Solomon H. Snyder Department of Neuroscience and Neurosurgery Pain Research Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

Ana Charrua

IBMC—Instituto de Biologia Molecular e Celular da Universidade do Porto

Departamento de Urologia, Faculdade de Medicina da Universidade do Porto and Departamento de Doenças Renais, Urológicas e Infecciosas, Faculdade de Medicina da Universidade do Porto, Porto, Portugal

Francisco Cruz

IBMC—Instituto de Biologia Molecular e Celular da Universidade do Porto

Departamento de Urologia, Faculdade de Medicina da Universidade do Porto

Departamento de Doenças Renais, Urológicas e Infecciosas, Faculdade de Medicina da Universidade do Porto and Departamento de Urologia, Hospital São João, Porto, Portugal

Matthew A.J. Duncton     Renovis, Inc. (a wholly owned subsidiary of Evotec AG), South San Francisco, California, USA

Madeleine Ennis     Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK

Susan Fleetwood-Walker     Centre for Integrative Physiology, School of Biomedical Sciences, College of Medicine & Veterinary Medicine, University of Edinburgh, Scotland, UK

Ehud Goldin     SENS Research Foundation, Mountain View, CA, USA

Arthur Gomtsyan     Department of Chemistry, Research and Development, AbbVie Inc., North Chicago, Illinois, USA

Huizhen Huang

Department of Neurobiology, University of Pittsburgh

Pittsburgh Center for Pain Research, Pittsburgh, PA, USA, and Tsinghua University School of Medicine, Beijing, China

Gerald Hunsberger     Neuronal Targets Team, Respiratory Therapy Area, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA

Michael J. Iadarola     Anesthesia Section, Department of Perioperative Medicine, Clinical Center, NIH, Bethesda, Maryland, USA

Neelima Khairatkar Joshi     Glenmark Research Centre, Navi Mumbai, Glenmark Pharmaceuticals Ltd, India

Pragyanshu Khare     Department of Nutritional Sciences and Technology, National Agri-Food Biotechnology Institute (NABI), SAS Nagar, India

Kirill Kiselyov     Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA, USA

Ari Koivisto     Research and Development, OrionPharma, Orion Corporation, Turku, Finland

Kanthi K. Kondepudi     Department of Food Sciences and Technology, National Agri-Food Biotechnology Institute (NABI), SAS Nagar, India

Artem Kondratskyi     Inserm U-1003, Equipe labellisée par la Ligue Nationale contre le cancer, Laboratory of Excellence Ion Channels Science and Therapeutics, Université Lille 1, Villeneuve d’Ascq, France

Ina Kraus-Stojanowic     Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Kiel, Germany

TinaMarie Lieu     Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia

Daoyan Liu     Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China

Nancy Luo     Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA

Lorcan McGarvey     Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK

Rory Mitchell     Centre for Integrative Physiology, School of Biomedical Sciences, College of Medicine & Veterinary Medicine, University of Edinburgh, Scotland, UK

Magdalene Moran     Hydra Biosciences Cambridge, MA, USA

Christopher Neipp     Flexible Discovery Unit, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA

Bernd Nilius     Katholieke Universiteit of Leuven, Department of Cellular and Molecular Medicine, Laboratory of Ion Channel Research and TRP Research Platform Leuven (TRPLe), Campus Gasthuisberg, Leuven, Belgium

James C. Parker     Department of Physiology and Center for Lung Biology, University of South Alabama, Mobile, Alabama, USA

Antti Pertovaara     Institute of Biomedicine/Physiology, University of Helsinki, Helsinki, Finland

Koenraad Philippaert     Katholieke Universiteit of Leuven, Department of Cellular and Molecular Medicine, Laboratory of Ion Channel Research and TRPLe (TRP Research Platform Leuven), Campus Gasthuisberg, Leuven, Belgium

Daniel P. Poole

Monash Institute of Pharmaceutical Sciences

Department of Anatomy & Cell Biology, The University of Melbourne, Parkville, Victoria, Australia

Louis S. Premkumar     Department of Pharmacology, Southern Illinois University-School of Medicine, Springfield, Illinois, USA

Natalia Prevarskaya     Inserm U-1003, Equipe labellisée par la Ligue Nationale contre le cancer, Laboratory of Excellence Ion Channels Science and Therapeutics, Université Lille 1, Villeneuve d’Ascq, France

Pradeep Rajasekhar     Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia

Paul Rosenberg     Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA

Sarah E. Ross

Department of Neurobiology

Department of Anesthesiology

Pittsburgh Center for Pain Research, and Center for Neuroscience Research at the University of Pittsburgh, Pittsburgh PA, USA

Kavisha Singh     Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA

Lindsey M. Snyder

Department of Neurobiology, University of...

Erscheint lt. Verlag 9.4.2015
Sprache englisch
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Studium 1. Studienabschnitt (Vorklinik) Physiologie
Naturwissenschaften Biologie Biochemie
Naturwissenschaften Biologie Humanbiologie
Naturwissenschaften Biologie Zoologie
ISBN-10 0-12-420079-6 / 0124200796
ISBN-13 978-0-12-420079-1 / 9780124200791
Haben Sie eine Frage zum Produkt?
PDFPDF (Adobe DRM)
Größe: 16,7 MB

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

EPUBEPUB (Adobe DRM)
Größe: 14,3 MB

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belle­tristik und Sach­büchern. Der Fließ­text wird dynamisch an die Display- und Schrift­größe ange­passt. Auch für mobile Lese­geräte ist EPUB daher gut geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich

von Hans-Christian Pape; Armin Kurtz; Stefan Silbernagl

eBook Download (2023)
Thieme (Verlag)
109,99

von Hans-Christian Pape; Armin Kurtz; Stefan Silbernagl

eBook Download (2023)
Thieme (Verlag)
109,99